| 摘要 |
Disclosed are methods for the alleviation of symptoms associated with inflammatory disease states, and more particularly to the inhibition of amatory processes associated with the multiple sclerosis disease, by administering a pharmaceutically effective amount of antibody substance immunologically reactive with the common beta chain (CD18) of human leukocyte integrins and/or competes with mAb 60.3 for binding to human LPA-1.
|
